These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24129679)

  • 21. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
    Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
    Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling.
    McKay MM; Ritt DA; Morrison DK
    Curr Biol; 2011 Apr; 21(7):563-8. PubMed ID: 21458265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evolution of melanoma resistance reveals therapeutic opportunities.
    Das Thakur M; Stuart DD
    Cancer Res; 2013 Oct; 73(20):6106-10. PubMed ID: 24097822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades.
    Matsubara M; Tamura T; Ohmori K; Hasegawa K
    Biochem Pharmacol; 2005 Feb; 69(3):433-49. PubMed ID: 15652235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
    Holderfield M; Lorenzana E; Weisburd B; Lomovasky L; Boussemart L; Lacroix L; Tomasic G; Favre M; Vagner S; Robert C; Ghoddusi M; Daniel D; Pryer N; McCormick F; Stuart D
    Cancer Res; 2014 Apr; 74(8):2238-45. PubMed ID: 24523442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK.
    Kubiniok P; Lavoie H; Therrien M; Thibault P
    Mol Cell Proteomics; 2017 Apr; 16(4):663-679. PubMed ID: 28188228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
    Shields JM; Thomas NE; Cregger M; Berger AJ; Leslie M; Torrice C; Hao H; Penland S; Arbiser J; Scott G; Zhou T; Bar-Eli M; Bear JE; Der CJ; Kaufmann WK; Rimm DL; Sharpless NE
    Cancer Res; 2007 Feb; 67(4):1502-12. PubMed ID: 17308088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
    Satyamoorthy K; Li G; Gerrero MR; Brose MS; Volpe P; Weber BL; Van Belle P; Elder DE; Herlyn M
    Cancer Res; 2003 Feb; 63(4):756-9. PubMed ID: 12591721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
    Favre G
    Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
    Rajakulendran T; Adam DN
    Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
    Guha S; Lunn JA; Santiskulvong C; Rozengurt E
    Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
    Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
    Chen J; Shen Q; Labow M; Gaither LA
    Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.